Skip to content

Visualisation of the Central Analgesic Effect of Paracetamol in Functional MRI

Visualisation of the Central Analgesic Effect of Paracetamol in Functional MRI

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01562704
Acronym
IRMf
Enrollment
21
Registered
2012-03-26
Start date
2012-01-31
Completion date
2012-04-30
Last updated
2013-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

mechanism of action of paracetamol in the brain structures

Brief summary

Paracetamol is one of the most widely used analgesic in the world, indicated for the symptomatic treatment of fever and pain. The objective of this study is to evaluate the mechanism of action of paracetamol (versus placebo) in the brain with new assessment tools (functional MRI and test inducing pain by thermal stimulation.

Detailed description

Visit 1 / Visit 2 Inclusion of the subject, Clinical examination Trainings tests Study period 1 Clinical examination Measurement of the basal pain thresholds Administration of product (T0) T0+100min : Thermal stimulation according to the established paradigm and fMRI data acquisition T0+180min : Thermal stimulation according to the established paradigm and fMRI data acquisition Study period 2: same of period 1.

Interventions

The objective of this study is to evaluate the mechanism of action of paracetamol (versus placebo) in the brain with new assessment tools (functional MRI and test inducing pain by thermal stimulation

Sponsors

Dr. Gisèle PICKERING (MCU, PH)
CollaboratorUNKNOWN
Dr. Betty JEAN (PH)
CollaboratorUNKNOWN
University Hospital, Clermont-Ferrand
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
MALE
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* \- Healthy volunteers * Aged at last 18 years and over 60 years * Male * Non-smoking subject * Fasting coffe, tea, coca-cola or other stimulant products since the last evening * Subject free of any treatment within 7 days prior to inclusion including no use of analgesics or anti-inflammatory treatments

Exclusion criteria

* Contraindications to the administration of paracetamol * Contraindications to the completion of MRI * Medical history and/or surgical judged by the investigator as being incompatible with the test * Progressive disease at the inclusion

Design outcomes

Primary

MeasureTime frame
Difference between the matrice plans obtained in both treatments (paracetamol or placebo) and 100 min after administration of paracetamol or placebo in brain structures100 min after administration of paracetamol or placebo

Secondary

MeasureTime frame
Difference between the matrice plans obtained in both treatments (paracetamol or placebo) and 180 min after administration of paracetamol or placebo in brain structures180 min after administration of paracetamol or placebo

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 16, 2026